Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-Small Cell Lung Cancer: Update Bulletin [October 2015]

Product Code:
Publication Date:
October 2015

Gain new KOL insights on the latest events with the potential to shape the targeted treatment of non-small cell lung cancer (NSCLC). Topics covered include opinions about Opdivo’s (nivolumab; Bristol-Myers Squibb) potential new role in non-squamous NSCLC therapy and its longer-term survival benefits for treating squamous NSCLC; Keytruda’s (pembrolizumab; Merck & Co.) approval for the second-line treatment of PD-L1 positive NSCLC; the recent release of positive results from the BIRCH trial of Roche’s atezolizumab; and promising early clinical data for the combination of Opdivo with Yervoy (ipilimumab; Bristol-Myers Squibb) in the first-line treatment of advanced NSCLC.

Key Questions Answered in this Update Bulletin:

  • Will the requirement for PD-L1 testing affect the extent to which Keytruda is used as a second-line treatment for NSCLC?
  • While the results of the BIRCH trial highlight atezolizumab’s potential as a therapy for PD-L1 positive NSCLC, how likely is it that this new PD-L1 inhibitor will demonstrate sufficient product differentiation to secure a role in this setting?
  • Do KOLs expect the longer-term survival benefits shown by Opdivo in the CheckMate-017 and CheckMate-063 trials to confirm its position as the standard of care for second-line squamous NSCLC?
  • Will the lower toxicity arising from the new dosing schedules for Opdivo plus Yervoy in the CheckMate-012 trial overcome KOLs’ safety concerns and increase the combination’s chance of success as a first-line therapy for advanced NSCLC?
  • As Opdivo awaits FDA approval for previously treated non-squamous NSCLC, do KOLs think the agent will prove as successful in this new setting as it has been in the treatment of squamous NSCLC?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved